Aurobindo Pharma’s wholly owned subsidiary -- Aurobindo Pharma USA Inc has entered into a definitive agreement with Lannett Seller Holdco, Inc under which Aurobindo Pharma USA Inc will acquire 100% of membership interest in Lannett Company LLC from Lannett Seller Holdco, Inc.
The transaction aligns with Aurobindo’s strategic objective to expand its U.S. manufacturing footprint by enhancing its existing domestic capabilities. Through this acquisition, Aurobindo will gain access to a complementary portfolio of profitable products, growing Contract Development and Manufacturing Organization (CDMO) business and U.S.-based manufacturing facility with significant excess capacity (425k sq ft facility with around 3.6 billion doses capacity) and with potential for further expansion.
The acquired product portfolio is primarily focused on non-opioid controlled substances, particularly in ADHD therapeutics for which Aurobindo currently has a limited presence. This acquisition strengthens Aurobindo’s ability to serve the U.S. generics space and provides strategic diversification into a specialized, high-value therapeutic category.
Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1668.00 |
| Dr. Reddys Lab | 1232.25 |
| Cipla | 1228.90 |
| Zydus Lifesciences | 936.35 |
| Lupin | 2328.60 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: